Inhibition of Hepatitis C Virus in Chimeric Mice by Short Synthetic Hairpin RNAs: Sequence Analysis of Surviving Virus Shows Added Selective Pressure of Combination Therapy

pH-Triggered Nanoparticle Mediated Delivery of siRNA to Liver Cells in Vitro and in Vivo

(2013) Soumia Kolli et al.   BIOCONJUGATE CHEMISTRY

Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials

(2013) James C. Sullivan et al.   CLINICAL INFECTIOUS DISEASES

Formulated Minimal-Length Synthetic Small Hairpin RNAs Are Potent Inhibitors of Hepatitis C Virus in Mice With Humanized Livers

(2013) Han Ma et al.   GASTROENTEROLOGY

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

(2013) Niu Shi et al.   GUT

Liver as a target for oligonucleotide therapeutics

(2013) Alfica Sehgal et al.   JOURNAL OF HEPATOLOGY

Hepatitis C in the United States

(2013) Scott D. Holmberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice

(2013) Anne Dallas et al.   Molecular Therapy-Nucleic Acids

Safety profile of RNAi nanomedicines

(2012) Scott A. Barros et al.   ADVANCED DRUG DELIVERY REVIEWS

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

(2012) Jin-Hua Sun et al.   HEPATOLOGY

HIV Develops Indirect Cross-resistance to Combinatorial RNAi Targeting Two Distinct and Spatially Distant Sites

(2012) Priya S Shah et al.   MOLECULAR THERAPY

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overcoming Barriers to Care for Hepatitis C

(2012) Paul J. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing

(2012) Anne Dallas et al.   NUCLEIC ACIDS RESEARCH

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells

(2012) Tatiana I Novobrantseva et al.   Molecular Therapy-Nucleic Acids

Response to “HIV Escape From RNAi Antivirals: Yet Another Houdini Action?”

(2012) Priya S Shah et al.   Molecular Therapy-Nucleic Acids

HIV-1 Escape From RNAi Antivirals: Yet Another Houdini Action?

(2012) Ben Berkhout et al.   Molecular Therapy-Nucleic Acids

In VitroCharacterization of the Activity of PF-05095808, a Novel Biological Agent for Hepatitis C Virus Therapy

(2011) Helen Lavender et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

(2011) Stefan Zeuzem et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

RNA Interference as a Tool for Exploring HIV-1 Robustness

(2011) Maria Nevot et al.   JOURNAL OF MOLECULAR BIOLOGY

Translation-competent 48S complex formation on HCV IRES requires the RNA-binding protein NSAP1

(2011) Sung Mi Park et al.   NUCLEIC ACIDS RESEARCH

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

(2011) M. H. Powdrill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Insights into the HCV Quasispecies and Compartmentalization

(2011) Patrizia Farci   SEMINARS IN LIVER DISEASE

Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor

(2010) N. Kamiya et al.   JOURNAL OF GENERAL VIROLOGY

Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity

(2010) K. Alsaleh et al.   JOURNAL OF VIROLOGY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Rational design of cationic lipids for siRNA delivery

(2010) Sean C Semple et al.   NATURE BIOTECHNOLOGY

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

(2010) Bambang S. Adiwijaya et al.   PLoS Computational Biology

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

(2009) Adam D. Judge et al.   JOURNAL OF CLINICAL INVESTIGATION

siRNA and Innate Immunity

(2009) Marjorie Robbins et al.   OLIGONUCLEOTIDES

Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs

(2009) Q. Ge et al.   RNA

Minimal-length short hairpin RNAs: The relationship of structure and RNAi activity

(2009) Q. Ge et al.   RNA

Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation

(2008) Marjorie Robbins et al.   HUMAN GENE THERAPY

Overcoming the Innate Immune Response to Small Interfering RNA

(2008) Adam Judge et al.   HUMAN GENE THERAPY

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

(2008) S. Le Pogam et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES